Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.

Moreno Márquez, CarolinaFernández Álvarez, PaulaValdés Delgado, TeresaCastro Laria, LuisaArgüelles Arias, FedericoCaunedo Álvarez, ÁngelGómez Rodríguez, Blas José2023-05-032023-05-0320221130-0108http://hdl.handle.net/10668/21704the primary goal of this study was to compare gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy supplemented with Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 6475) or placebo. this was a randomized, double-blind, parallel-arm, placebo-controlled clinical trial. Patients received a first-line eradication regimen based on bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (three-in-one capsules) and omeprazole 40 mg twice a day for ten days, plus a probiotic or placebo tablet for 30 days. During follow-up, gastrointestinal symptoms were assessed using an evaluation scale (GSRS), and adverse events were collected at 0, 14, 28 and 56 days. a total of 80 patients were included from February 2018 to May 2019 at a single site. Eradication therapy was effective in 85 % of patients, with no differences between treatment arms. In the group receiving the probiotic, abdominal pain decreased in 42 % of patients, compared with 19 % in the control group (OR: 0.27; CI, 0.13-0.58; penAbdominal PainAnti-Bacterial AgentsBismuthDrug Therapy, CombinationHelicobacter InfectionsHelicobacter pyloriHumansLimosilactobacillus reuteriMetronidazoleProbioticsTreatment OutcomeRandomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.research article33947195open access10.17235/reed.2021.7931/2021https://online.reed.es/DOI/PDF/ArticuloDOI_7931.pdf